Skip to main content
Premium Trial:

Request an Annual Quote

Genetic Technologies Names New Chairman, Acting CEO

NEW YORK (GenomeWeb News) – A day after its chairman's re-election was blocked and its CEO resigned, Genetic Technologies named a new chairman and acting CEO today.

The Australian firm named Mal Brandon, a current board member, as its new chairman of the board of directors. The firm also said that COO Alison Mew has been named acting CEO.

The appointments come a day after the firm's annual general meeting, at which Chairman Mel Bridges and Director Huw Jones were not re-elected to the firm's board — apparently due to the efforts of Founder Mervyn Jacobson, who used his 29 percent stake to block their re-election. Following the meeting, CEO Paul MacLeman, Director Greg Brown, and VP of Legal and Corporate Development David Sparling all resigned.

The firm did not respond to an email from GenomeWeb Daily News seeking further information and comment.

"The board is confident that the company will continue to build on the solid foundation that has been created and looks forward to further expansion of its US operations and its global licensing programs," Brandon said in a statement issued today.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.